| Course | MPH 515 Epidemiology and Biostatistics for Public Health Application I |
|---|---|
| Week | 8 |
| Paper type | Epidemiology synthesis paper |
| Length | About 1,120 words, 5 pages |
| Format | APA 7 student paper |
| School | Chamberlain University |
| Program | Master of Public Health (MPH) |
| Updated | October 2026 |
Free sample paper for MPH 515 Week 8
Epidemiology Synthesis: Should Bellamy County Offer Emergency Department Buprenorphine and Follow-Up to Every Resident Treated for a Nonfatal Opioid Overdose?
Student Name
Chamberlain University
MPH 515: Epidemiology and Biostatistics for Public Health Application I
Instructor Name
Month Day, Year
Epidemiology Synthesis: Should Bellamy County Offer Emergency Department Buprenorphine and Follow-Up to Every Resident Treated for a Nonfatal Opioid Overdose?
The Question
This paper asks whether the evidence supports Bellamy County, the composite Midwestern county used throughout this course, in funding all three of its hospitals' emergency departments to offer buprenorphine and a peer recovery follow-up to every resident treated for a nonfatal opioid overdose. Today only one of the three hospitals offers buprenorphine routinely. The question has two parts: how large is the burden among residents treated for nonfatal overdose, and how confident can the county be that offering treatment in the emergency department reduces it?
Burden, With the Right Measure
The measure of how often new cases occur is the incidence rate. From January 2023 to December 2024, 1,241 residents were seen for the first time after surviving an opioid overdose, which works out to 150.1 per 100,000 person-years. The rate was highest among residents aged 25 to 44, 322.4 per 100,000, and among men, 1.85 times the rate in women. The rate fell from 159.0 in 2023 to 141.2 in 2024, so that 2024 ran at 0.89 times the 2023 rate (interval 0.79 to 0.99), a modest decline that may partly reflect coding or care-seeking changes.
Incidence describes how many people enter the group at risk, but the decision depends on what happens to them afterward. The 1,241 residents made 1,489 visits, so about one visit in six was a repeat. And people treated for nonfatal overdose die at high rates afterward: a Massachusetts cohort lost about one patient in eighteen within a year of the emergency visit, and a fifth of those deaths came in the first month (Weiner et al., 2020). Applied to Bellamy County's roughly 600 first visits a year, that rate would imply about 33 deaths within a year, if the county's patients resemble Massachusetts patients, which is an assumption. The burden that the proposed program addresses is therefore not only the visits but the deaths that follow them.
What Is Known, With Designs Named and Weighed
Three kinds of evidence bear on the question, and they differ in what their designs can establish.
A randomized controlled trial. D'Onofrio et al. (2015) randomized 329 opioid-dependent patients in one urban emergency department to referral, brief intervention with facilitated referral, or brief intervention plus emergency department-initiated buprenorphine. A month after enrollment, 78% of the buprenorphine arm were in addiction care, against 37% of the referral arm and 45% of the brief intervention arm, and the buprenorphine arm cut its weekly days of illicit opioid use the most (D'Onofrio et al., 2015). Randomization makes this the strongest evidence of an effect on treatment engagement. Its limits are that it was conducted in one academic hospital, enrolled patients with opioid dependence rather than only those presenting after overdose, and measured engagement and drug use rather than overdose or death.
A local observational analysis. In Bellamy County, residents who started buprenorphine at the one hospital that offers it were about half as likely to come back with another overdose inside a month, a risk ratio of 0.48 with an interval of 0.27 to 0.87. This analysis has the advantage of being about the county's own patients and an outcome that matters, but it is observational, and the patients who said yes to treatment were not a random half of those offered it.
A cohort study of outcomes after overdose. Weiner et al. (2020) followed patients after emergency treatment for nonfatal overdose through linked statewide data. Its design establishes the high risk in the period after a visit, which defines the opportunity, but it does not test any intervention.
Table 1
Evidence Bearing on Emergency Department Buprenorphine in Bellamy County
| Source | Design | What it can establish | Main limit for this question |
|---|---|---|---|
| D'Onofrio et al. (2015) | Randomized trial, one hospital | Buprenorphine start increases treatment engagement at 30 days | Engagement, not overdose or death; one academic site |
| County analysis, 2024 | Observational, local | Association with fewer repeat visits in county patients | Confounding by who accepts treatment |
| Weiner et al. (2020) | Retrospective cohort, statewide | High mortality after nonfatal overdose | No intervention tested |
Note. Note. County analysis uses composite data constructed for this course.
Confidence, Stated
Confidence is high that the post-overdose period carries substantial risk of death, high that emergency department buprenorphine increases treatment engagement in the short term, and moderate that it reduces repeat overdose in Bellamy County. Confidence is low that it reduces deaths, because no source here measures deaths as an outcome of the intervention. The evidence is consistent in direction across designs, which strengthens it, but each design leaves a different gap.
What Would Settle It
Two kinds of evidence would settle the remaining questions for the county. First, a staged rollout to the two hospitals that do not yet offer buprenorphine, with start dates set by lot, would allow comparison of repeat visits and deaths at hospitals before and after implementation, a design stronger than the current observational comparison. Second, linkage of emergency visit data with county death records would allow the county to measure 30-day and one-year mortality after overdose visits, before and after the rollout. Both use data the county already collects.
Recommendation, Scaled to the Evidence
The evidence supports expanding emergency department buprenorphine to all three hospitals, because the burden is high, the intervention increases treatment engagement in a randomized trial, local figures lean the same way and the risks of offering it are low. The evidence does not yet support claiming that the expansion will reduce overdose deaths by any particular amount, and the county's board should not be told it will. The recommendation is therefore to expand through a staged rollout over 12 months, with start dates set by lot, peer follow-up within 72 hours of discharge and linkage to death records, so that the expansion produces evidence on the outcome the county cares about most. The board should expect a report at 18 months that states what changed in repeat visits and deaths, with intervals, and what remains uncertain.
What the Recommendation Does Not Cover
The recommendation addresses residents who reach an emergency department. It does not reach those who overdose and never arrive, which the county's 2024 tables suggest may be a larger share in the rural south. Naloxone distribution and outreach there are separate decisions with their own evidence, including the Massachusetts finding that communities with more naloxone distribution had lower overdose death rates (Walley et al., 2013).
References
D'Onofrio, G., O'Connor, P. G., Pantalon, M. V., Chawarski, M. C., Busch, S. H., Owens, P. H., Bernstein, S. L., & Fiellin, D. A. (2015). Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: A randomized clinical trial. JAMA, 313(16), 1636-1644. https://doi.org/10.1001/jama.2015.3474
Walley, A. Y., Xuan, Z., Hackman, H. H., Quinn, E., Doe-Simkins, M., Sorensen-Alawad, A., Ruiz, S., & Ozonoff, A. (2013). Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: Interrupted time series analysis. BMJ, 346, f174. https://doi.org/10.1136/bmj.f174
Weiner, S. G., Baker, O., Bernson, D., & Schuur, J. D. (2020). One-year mortality of patients after emergency department treatment for nonfatal opioid overdose. Annals of Emergency Medicine, 75(1), 13-17. https://doi.org/10.1016/j.annemergmed.2019.04.020
The Chamberlain MPH 515 Week 8 instructions
The final week asks for a synthesis paper that answers an epidemiologic question about a population using the term's tools where each one fits. Pose a clear question tied to a decision. Describe the burden with the measure that suits the question. Bring in evidence from studies whose designs you name and weigh, explaining what each can and cannot establish. State how confident you are in each part of the answer. Say what evidence would settle the remaining uncertainty. Make a recommendation scaled to the strength of the evidence, not to the seriousness of the problem. Use earlier assignments where they help, but do not demonstrate every calculation for its own sake.
Inside the MPH 515 Week 8 example
The paper asks whether all three hospitals in a composite county should offer buprenorphine with peer follow-up after nonfatal overdose. Burden is given by incidence, repeat visits and the Massachusetts finding that about one patient in eighteen died within a year of such a visit. A table weighs the D'Onofrio randomized trial, which showed higher treatment engagement at 30 days, the county's own observational association with fewer repeat visits, and the Weiner cohort, which shows risk but tests no intervention. Confidence is stated claim by claim. A staged rollout with start dates set by lot and linkage to death records would settle the rest, so the recommendation is expansion through that design.
MPH 515 Week 8 rubric: what full points look like
The characteristic loss on this paper is the demonstration: every measure calculated, every design described and every test mentioned, with no argument running through them. It shows the course was completed, not that judgment was formed. A recommendation scaled to the seriousness of the problem rather than the strength of the evidence is the second common weakness. Evidence listed without weighing designs, confidence never stated and no account of what would settle the question also cost points. Strong papers pose a decision-linked question, choose the right burden measure, weigh designs, state confidence, name what would settle the matter and scale the recommendation to the evidence. Recommendations that promise outcomes no study measured also lose credit.
MPH 515 Week 8 help: mistakes that cost points
Synthesis papers are where students most often fall back on showing everything they learned. If you share your question and the work you did earlier in the term, we can help you choose which measures and studies belong, weigh designs against one another and state confidence clearly for each claim. We can also help you write a recommendation that matches the evidence rather than the urgency of the problem. Your question and judgments remain your own. If your section requires a set structure, such as background, methods, results and discussion, send it so the custom sample keeps the argument inside that frame. We can also help you state what your recommendation does not cover, which keeps it honest about the population the evidence reaches.
Get a MPH-515 Week 8 example written to your instructions
Send the Week 8 instructions with the element list your section publishes and the question you are working on, and a custom example is written to those requirements and returned inside 24 to 48 hours. The first one is free. Which question you pursue across the term stays yours.
More MPH 515 papers and MPH samples
- MPH 515 Week 1: Population Question Post
- MPH 515 Week 2: Epidemiologic Measures Write-Up
- MPH 515 Week 3: Study Design Critique
- MPH 515 Week 4: Sample Paper, in Real Form
- MPH 515 Week 5: Biostatistics Write-Up
- MPH 515 Week 6: Hypothesis Testing Exercise
- MPH 515 Week 7: Data Interpretation Paper
- MPH 509 Week 8: CBPR Project Proposal
- MPH 508 Week 8: Leadership Reflection
- MPH 507 Week 8: Program Evaluation Proposal
- MPH 500 Week 8: Synthesis Presentation
MPH 515 Week 8 questions, answered
Do I have to use every method from the course?
No, and trying to is the commonest way this paper goes wrong. Use what the question needs and say why the others do not apply where that is worth saying. A paper using three tools well argues something; one using eight demonstrates coverage, and coverage is not what a synthesis rubric is looking for.
How do I weigh studies against each other?
By what each design can establish and by how well it was executed, in that order. A well-conducted cohort study outweighs a large cross-sectional one for a question about sequence, whatever their sample sizes. Saying so explicitly is the move that turns a literature summary into a synthesis.
What if the evidence is genuinely mixed?
Report that as the finding, propose why the studies differ, and scale the recommendation accordingly. Populations, exposure definitions and follow-up periods explain most disagreement in the literature. A paper that reports mixed evidence and reasons about it reads as competent, while one that resolves the mixture by ignoring half of it does not.
Where can I find a free MPH 515 Week 8 sample paper?
This page holds the complete MPH 515 Week 8 synthesis on emergency department buprenorphine after nonfatal overdose, with designs weighed.
What does the MPH 515 Week 8 sample recommend?
Expanding emergency department buprenorphine to all three hospitals through a staged rollout with linkage to death records, without promising a set fall in deaths.